Glanzmann's thrombasthenia diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Okamal (talk | contribs)
nocaptcha
1,371 edits
No edit summary
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Bot: Removing from Primary care
 
(4 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Glanzmann's thrombasthenia}}
{{Glanzmann's thrombasthenia}}


{{CMG}} {{AE}} {{OK}}, [[User:Niush.D|Niyousha Danesh, MD-MPH]]  
{{CMG}} {{shyam}} {{AE}} {{OK}}, [[User:Niush.D|Niyousha Danesh, MD-MPH]]  


==Overview==
==Overview==
'''Platelet aggregation assays''' — Traditional platelet aggregation assays employ a panel of platelet agonists to measure platelet activation and aggregation in vitro. Either whole blood or platelet-rich plasma is used depending on the technique. Since many common medications can affect platelet function, care must be taken to avoid their use in patients prior to testing. Common agonists used in these assays include ADP, arachidonic acid, collagen, epinephrine, thrombin, and ristocetin. Platelet function testing", section on 'Platelet aggregometry'.)
There is no single study of choice for the [[diagnosis]] of [[Glanzmann's thrombasthenia]], but it can be diagnosed based on [[platelet aggregation]] [[assays]] which constitute a panel of [[assays]] measuring platelet aggregation and activation ''in vitro'' using agonists like [[ADP]], [[arachidonic acid]], [[collagen]], [[epinephrine]], [[thrombin]], and [[ristocetin]].The diagnosis of [[Glanzmann's thrombasthenia|Glanzmann thrombasthenia]] is confirmed through monoclonal antibody testing and [[flow cytometry]].


== Diagnostic study of choice ==
== Diagnostic study of choice ==
There is no single diagnostic study of choice for the diagnosis of Glanzmann's thrombasthenia, but it can be diagnosed based on '''Platelet aggregation assays''' — Traditional platelet aggregation assays employ a panel of platelet agonists to measure platelet activation and aggregation in vitro. Either whole blood or platelet-rich plasma is used depending on the technique. Since many common medications can affect platelet function, care must be taken to avoid their use in patients prior to testing. Common agonists used in these assays include ADP, arachidonic acid, collagen, epinephrine, thrombin, and ristocetin. (See "Platelet function testing", section on 'Platelet aggregometry'.)<ref name="pmid19775303">{{cite journal |vauthors=Quiroga T, Goycoolea M, Matus V, Zúñiga P, Martínez C, Garrido M, Aranda E, Leighton F, Panes O, Pereira J, Mezzano D |title=Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays |journal=Br. J. Haematol. |volume=147 |issue=5 |pages=729–36 |date=December 2009 |pmid=19775303 |doi=10.1111/j.1365-2141.2009.07890.x |url=}}</ref><ref name="pmid18663056">{{cite journal |vauthors=Jennings I, Woods TA, Kitchen S, Walker ID |title=Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006 |journal=J. Clin. Pathol. |volume=61 |issue=8 |pages=950–4 |date=August 2008 |pmid=18663056 |doi=10.1136/jcp.2008.057174 |url=}}</ref><ref name="pmid19422455">{{cite journal |vauthors=Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD |title=Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=7 |issue=6 |pages=1029 |date=June 2009 |pmid=19422455 |doi=10.1111/j.1538-7836.2009.03458.x |url=}}</ref><ref name="pmid19143930">{{cite journal |vauthors=Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, Cook RJ, Heddle NM |title=Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments |journal=J. Thromb. Haemost. |volume=7 |issue=4 |pages=676–84 |date=April 2009 |pmid=19143930 |doi=10.1111/j.1538-7836.2009.03273.x |url=}}</ref><ref name="pmid13871375">{{cite journal |vauthors=BORN GV |title=Aggregation of blood platelets by adenosine diphosphate and its reversal |journal=Nature |volume=194 |issue= |pages=927–9 |date=June 1962 |pmid=13871375 |doi= |url=}}</ref>
There is no single study of choice for the diagnosis of [[Glanzmann's thrombasthenia]], but it can be diagnosed based on [[platelet aggregation]] [[assays]] which constitute a panel of [[assays]] measuring platelet aggregation and activation ''in vitro''. Agonists that are used in this laboratory test include [[ADP]], [[arachidonic acid]], [[collagen]], [[epinephrine]], [[thrombin]], and [[ristocetin]]. The diagnosis of [[Glanzmann's thrombasthenia|Glanzmann thrombasthenia]] is confirmed through monoclonal antibody testing and [[flow cytometry]] <ref name="pmid19775303">{{cite journal |vauthors=Quiroga T, Goycoolea M, Matus V, Zúñiga P, Martínez C, Garrido M, Aranda E, Leighton F, Panes O, Pereira J, Mezzano D |title=Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays |journal=Br. J. Haematol. |volume=147 |issue=5 |pages=729–36 |date=December 2009 |pmid=19775303 |doi=10.1111/j.1365-2141.2009.07890.x |url=}}</ref><ref name="pmid18663056">{{cite journal |vauthors=Jennings I, Woods TA, Kitchen S, Walker ID |title=Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006 |journal=J. Clin. Pathol. |volume=61 |issue=8 |pages=950–4 |date=August 2008 |pmid=18663056 |doi=10.1136/jcp.2008.057174 |url=}}</ref><ref name="pmid19422455">{{cite journal |vauthors=Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD |title=Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=7 |issue=6 |pages=1029 |date=June 2009 |pmid=19422455 |doi=10.1111/j.1538-7836.2009.03458.x |url=}}</ref><ref name="pmid19143930">{{cite journal |vauthors=Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, Cook RJ, Heddle NM |title=Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments |journal=J. Thromb. Haemost. |volume=7 |issue=4 |pages=676–84 |date=April 2009 |pmid=19143930 |doi=10.1111/j.1538-7836.2009.03273.x |url=}}</ref><ref name="pmid13871375">{{cite journal |vauthors=BORN GV |title=Aggregation of blood platelets by adenosine diphosphate and its reversal |journal=Nature |volume=194 |issue= |pages=927–9 |date=June 1962 |pmid=13871375 |doi= |url=}}</ref>


==References==
==References==
Line 15: Line 15:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Primary care]]

Latest revision as of 21:52, 29 July 2020

Glanzmann's thrombasthenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glanzmann's thrombasthenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glanzmann's thrombasthenia diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glanzmann's thrombasthenia diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glanzmann's thrombasthenia diagnostic study of choice

CDC on Glanzmann's thrombasthenia diagnostic study of choice

Glanzmann's thrombasthenia diagnostic study of choice in the news

Blogs on Glanzmann's thrombasthenia diagnostic study of choice

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Glanzmann's thrombasthenia diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[3], Niyousha Danesh, MD-MPH

Overview

There is no single study of choice for the diagnosis of Glanzmann's thrombasthenia, but it can be diagnosed based on platelet aggregation assays which constitute a panel of assays measuring platelet aggregation and activation in vitro using agonists like ADP, arachidonic acid, collagen, epinephrine, thrombin, and ristocetin.The diagnosis of Glanzmann thrombasthenia is confirmed through monoclonal antibody testing and flow cytometry.

Diagnostic study of choice

There is no single study of choice for the diagnosis of Glanzmann's thrombasthenia, but it can be diagnosed based on platelet aggregation assays which constitute a panel of assays measuring platelet aggregation and activation in vitro. Agonists that are used in this laboratory test include ADP, arachidonic acid, collagen, epinephrine, thrombin, and ristocetin. The diagnosis of Glanzmann thrombasthenia is confirmed through monoclonal antibody testing and flow cytometry [1][2][3][4][5]

References

  1. ↑ Quiroga T, Goycoolea M, Matus V, Zúñiga P, Martínez C, Garrido M, Aranda E, Leighton F, Panes O, Pereira J, Mezzano D (December 2009). "Diagnosis of mild platelet function disorders. Reliability and usefulness of light transmission platelet aggregation and serotonin secretion assays". Br. J. Haematol. 147 (5): 729–36. doi:10.1111/j.1365-2141.2009.07890.x. PMID 19775303.
  2. ↑ Jennings I, Woods TA, Kitchen S, Walker ID (August 2008). "Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006". J. Clin. Pathol. 61 (8): 950–4. doi:10.1136/jcp.2008.057174. PMID 18663056.
  3. ↑ Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD (June 2009). "Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH". J. Thromb. Haemost. 7 (6): 1029. doi:10.1111/j.1538-7836.2009.03458.x. PMID 19422455.
  4. ↑ Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, Cook RJ, Heddle NM (April 2009). "Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments". J. Thromb. Haemost. 7 (4): 676–84. doi:10.1111/j.1538-7836.2009.03273.x. PMID 19143930.
  5. ↑ BORN GV (June 1962). "Aggregation of blood platelets by adenosine diphosphate and its reversal". Nature. 194: 927–9. PMID 13871375.
Retrieved from "https://www.wikidoc.org/index.php?title=Glanzmann%27s_thrombasthenia_diagnostic_study_of_choice&oldid=1638520"